Merck Closes Acquisition of Sirna Therapeutics | GenomeWeb
NEW YORK (GenomeWeb News) — Merck has closed its $1.1-billion cash acquisition of Sirna Therapeutics, Merck said last week.
Merck originally announced its plan to acquire the RNAi company on Oct. 30, 2006, but waited for regulatory approval and for Sirna shareholders to give the nod, which they did on Dec. 28, 2006.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.